GW Pharma’s Epidiolex Receives Orphan Drug Designation in Europe


gw logoGW Pharmaceuticals Announces Epidiolex(R) Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome

LONDON, March 29, 2017 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics

... read more at: https://www.newcannabisventures.com/gw-pharmas-epidiolex-receives-orphan-drug-designation-in-europe/

by